Tenax Therapeutics (TENX) Cash from Operations (2010 - 2026)

Tenax Therapeutics has reported Cash from Operations for 17 years, with the latest figure at 14191000.0 in Q2 2026.

• Cash from Operations for Q2 2026 came in at 14191000.0, down 127.78% year-over-year; the trailing twelve-month figure through Jun 2026 was 46070000.0 (down 132.2% YoY), and the FY2025 annual result was 35800000.0, down 141.71% from the prior year.
• Cash from Operations declined to 14191000.0 in Q2 2026, from 9309000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 922966.0 in Q2 2023 and troughed at 14191000.0 in Q2 2026.
• A 5-year average of 5077976.17 and a median of 3381057.0 in 2022 frame the typical range for Cash from Operations.
• The widest annual swing landed in 2023, when Cash from Operations jumped 73.1%; it then plunged 281.66% in 2025.
• A 5-year view of Cash from Operations shows it stood at 1688780.0 in 2022, then surged by 30.42% to 1175008.0 in 2023, then tumbled by 198.81% to 3511000.0 in 2024, then plunged by 281.66% to 13400000.0 in 2025, then declined by 5.9% to 14191000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 14191000.0 in Q2 2026, 9309000.0 in Q1 2026, and 13400000.0 in Q4 2025.